Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Macular Diseases

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

BMJ Open Ophthalmol

Saad A, Plasencia C, Garweg J, Pfister IB, Munk MR, Eandi CM, Zweifel SA, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambersin A, Froehlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K

doi: 10.1136/bmjophth-2025-002467

Macular Diseases

Beyond Central Subfield Thickness: Early Multi-Slice Optical Coherence Tomography Structural Response After Faricimab Injection in Real-World Diabetic Macular Edema

J Clin Med

Liu DY, Wu SL, Hsia NY, Tien PT, Lin CJ, Wang I, Lai CT, Lin JM, Huang YT, Wu BQ, Lin WN, Ku WN, Meng PP, Chen HS, Tsai YY

doi: 10.3390/jcm15166356

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Macular Diseases

Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes

BMC Ophthalmol

Konttinen A, Wirkkala J, Kubin AM, Ohtonen P, Hautala N

doi: 10.1186/s12886-026-05083-2

Macular Diseases

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Ophthalmology

Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators

doi: 10.1016/j.ophtha.2025.10.028

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular DiseasesFurther Publications

Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence

BMC Ophthalmol

Owlya N, Barbosa M, Bartolomeo N, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Barry MP, Ambresin A

doi: 10.1186/s12886-026-04651-w

Further Publications

Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis

Retina

Sather RN 3rd, Chiang T, Moon JY, Dev S, Belin PJ

doi: 10.1097/IAE.0000000000004813

Related content

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

Beyond Central Subfield Thickness: Early Multi-Slice Optical Coherence Tomography Structural Response After Faricimab Injection in Real-World Diabetic Macular Edema

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Assessment of real-life visual outcomes and treatment efficacy of diabetic macular edema in patients with type 2 diabetes

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence

Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis